期刊
EXPERT OPINION ON PHARMACOTHERAPY
卷 16, 期 11, 页码 1577-1591出版社
TAYLOR & FRANCIS LTD
DOI: 10.1517/14656566.2015.1055250
关键词
body mass index; canagliflozin; Japanese; safety; type 2 diabetes mellitus
资金
- Mitsubishi Tanabe Pharma Corp.
- Astellas Pharma Inc.
- AstraZeneca K.K.
- Bristol-Myers K.K.
- Daiichi Sankyo Co., Ltd.
- Eli Lilly Japan K.K.
- GlaxoSmithKline K.K.
- Japan Tobacco Inc.
- Kissei Pharmaceutical Co., Ltd.
- Kyowa Hakko Kirin Co., Ltd.
- MSD K.K.
- Nippon Boehringer Ingelheim Co., Ltd.
- Novartis Pharma K.K.
- Novo Nordisk Pharma Ltd.
- Ono Pharmaceutical Co., Ltd.
- Pfizer Japan Inc.
- Roche Diagnostics K.K.
- Sanofi K.K.
- Shiratori Pharmaceutical Co., Ltd.
- Sumitomo Dainippon Pharma Co., Ltd.
- Taisho Pharmaceutical Co., Ltd.
- Takeda Pharmaceutical Co., Ltd.
Background: The safety and efficacy of sodium glucose co-transporter 2 inhibitors in non-obese compared with obese patients with type 2 diabetes mellitus is unknown. Methods: We conducted post hoc analyses of the results of a 52-week open-label study of Japanese type 2 diabetes mellitus patients treated with 100 or 200 mg canagliflozin. Patients were divided into four subgroups according to their baseline body mass index (BMI): group I, BMI < 22 kg/m(2); group II, BMI >= 22 to < 25 kg/m(2); group III, BMI >= 25 to < 30 kg/m(2) and group IV, BMI >= 30 kg/m(2). Results: The overall safety was similar among the four BMI subgroups, although there were slight differences in terms of the incidences of hypoglycemia, asymptomatic hypoglycemia, female genital infections and proportions of patients with total ketone body levels exceeding 1000 mu mol/l at any time for both canagliflozin doses. Hemoglobin A1c, fasting plasma glucose and body weight decreased significantly from baseline to week 52 at both canagliflozin doses. The changes in hemoglobin A1c, and fasting plasma glucose were not significantly different among the four BMI subgroups for either dose. Conclusion: Canagliflozin was tolerated in patients irrespective of their BMI at the start of treatment, although some caution may be needed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据